データ力を駆使したシステムが、何百万人もの患者の健康状態を改善する
ヘルスケアへ革新的で個別化されたアプローチを提供する上で、中心的な役割を果たしているのがデータです。個別化医療または精密医療は現在成長を遂げている分野で、科学的プロセス、テクノロジー、エビデンスを適用することにより、個々の患者の予防、診断、治療、そして、大規模な疾患管理における最適化を目指しています。
Tiffany Boughtwood (BSc MBA) is the Program Manager of the Australian Genomics Health Alliance (Australian Genomics), responsible for the executive operations of this collaborative research network across Australia.
Tiffany has over 20 years’ experience in molecular biology and research management. She has led accredited genomic sequencing facilities, operated academic and accredited diagnostic laboratories, engaged in research in neurodegenerative diseases and cancer, and consulted in genomic implementation and project management.
Over the past three years with Australian Genomics, Tiffany has managed a distributed network of staff to support the coordination, delivery and process evaluation of this large $55M program of work. In this time, the Australian Genomics collaboration has tripled in size to over 80 partner institutions, and 450 investigators and collaborators. It enrols participants across every Australian state and territory through 32 hospitals, into clinical flagship projects in rare diseases, cancers and reproductive carrier screening. 25,000 Australians will be enrolled and offered genomic healthcare through Australian Genomics-led programs by 2022.
Tiffany is a passionate proponent of the potential of genomics in healthcare, and is dedicated to the delivery of the Australian Genomics vision both locally, and internationally.
ヘルスケアへ革新的で個別化されたアプローチを提供する上で、中心的な役割を果たしているのがデータです。個別化医療または精密医療は現在成長を遂げている分野で、科学的プロセス、テクノロジー、エビデンスを適用することにより、個々の患者の予防、診断、治療、そして、大規模な疾患管理における最適化を目指しています。
The World Economic Forum, Australian Genomics and Genomics4RD have developed a governance model to drive innovation and mitigate risks of data sharing.
Genomics is emerging as a key source of data in healthcare. The benefits could be enormous, but we need to have a public debate about the risks and rewards.
There has never been a more important time to start a public conversation about genomics. Could a global PR campaign help to demystify this technology?